InMed Pharmaceuticals (INM) gets 9.9% passive stake from Sabby group

Rhea-AI Filing Summary

Sabby Volatility Warrant Master Fund, Ltd., together with Sabby Management, LLC and Hal Mintz, reports beneficial ownership of 280,138 shares of InMed Pharmaceuticals Inc. common stock, representing 9.9% of the class as of 12/31/2025. The group has shared power to vote and dispose of these shares, with no sole voting or dispositive power reported by any party.

The filers certify that the securities were not acquired and are not held for the purpose of changing or influencing control of InMed, and that their holdings are not connected with any control-related transaction, other than activities solely in connection with a nomination under the specified proxy rule.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

InMed Pharmaceuticals Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

457637700

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 457637700

1

Names of Reporting Persons

SABBY MANAGEMENT, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 280,138.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 280,138.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

280,138.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.9 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

CUSIP No. 457637700

1

Names of Reporting Persons

Hal Mintz

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

FLORIDA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 280,138.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 280,138.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

280,138.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.9 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

CUSIP No. 457637700

1

Names of Reporting Persons

Sabby Volatility Warrant Master Fund, Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 280,138.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 280,138.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

280,138.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.9 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: InMed Pharmaceuticals Inc.
(b)	Address of issuer's principal executive offices: 1445-885 WEST GEORGIA ST., VANCOUVER, BRITISH COLUMBIA, CANADA, V6C 3E8
Item 2.
(a)	Name of person filing: Sabby Volatility Warrant Master Fund, Ltd. Sabby Management, LLC Hal Mintz
(b)	Address or principal business office or, if none, residence: Sabby Volatility Warrant Master Fund, Ltd. c/o Captiva (Cayman) Ltd Governors Square, Bldg 4, 2nd Floor 23 Lime Tree Bay Avenue P.O. Box 32315 Grand Cayman KY1-1209 Cayman Islands Sabby Management, LLC 1011 Links Dr. Miami Beach, FL 33109 Hal Mintz c/o Sabby Management, LLC 1011 LInks Dr. Miami Beach, FL 33109
(c)	Citizenship: Sabby Volatility Warrant Master Fund, Ltd. - Cayman Islands Sabby Management, LLC - Delaware, USA Hal Mintz - USA
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 457637700
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Sabby Volatility Warrant Master Fund, Ltd. - 280,138 Sabby Management, LLC - 280,138 Hal Mintz - 280,138
(b)	Percent of class: Sabby Volatility Warrant Master Fund, Ltd. - 9.9% Sabby Management, LLC - 9.9% Hal Mintz - 9.9%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 280,138
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 280,138
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

SABBY MANAGEMENT, LLC

Signature:	/s/ Robert Grundstein
Name/Title:	COO
Date:	01/20/2026

Hal Mintz

Signature:	/S/ HAL MINTZ
Name/Title:	HAL MINTZ
Date:	01/20/2026

Sabby Volatility Warrant Master Fund, Ltd.

Signature:	/s/ Harry Thompson
Name/Title:	Harry Thompson
Date:	01/20/2026

FAQ

How many InMed (INM) shares are reported as beneficially owned in this Schedule 13G?

The filing reports that 280,138 shares of InMed Pharmaceuticals Inc. common stock are beneficially owned.

What percentage of InMed (INM) common stock does the Sabby group report owning?

The reporting persons state that they beneficially own 9.9% of InMed Pharmaceuticals Inc.'s outstanding common stock.

Who are the reporting persons in this InMed (INM) Schedule 13G filing?

The reporting persons are Sabby Volatility Warrant Master Fund, Ltd., Sabby Management, LLC, and Hal Mintz.

Do the reporting persons have sole or shared voting power over the InMed (INM) shares?

The filing shows 0 shares with sole voting power and 280,138 shares with shared voting power and shared dispositive power for each reporting person.

Is the Sabby group seeking to influence control of InMed Pharmaceuticals (INM)?

No. The certifying language states the securities were not acquired and are not held for the purpose or effect of changing or influencing control of InMed Pharmaceuticals Inc.

What is the date of the ownership event reported for InMed (INM)?

The date of the event requiring this Schedule 13G filing is 12/31/2025.

What type of securities of InMed (INM) are covered in this Schedule 13G?

The filing relates to common stock of InMed Pharmaceuticals Inc., identified by CUSIP 457637700.